Thermo Fisher Scientific announced the launch of the Gibco™ CTS™ DynaXS™ Single‑Use Bioreactor on May 4, 2026. The new platform is part of the company’s Cell Therapy Systems portfolio and is designed to give cell‑therapy developers a scalable, single‑use solution that offers precise process control, flexibility across a wide range of volumes and cell types, and regulatory readiness. By providing a ready‑to‑use system, Thermo Fisher aims to shorten setup time and lower operational costs for biopharma customers.
The launch comes as the cell‑therapy manufacturing market is projected to grow to USD 74.41 billion by 2035, with a CAGR of 16.96 % from 2026 to 2035. In 2025, cell‑therapy manufacturing services were valued at USD 15.59 billion, underscoring the large addressable opportunity. Thermo Fisher’s competitors in the single‑use bioreactor space include Lonza Group AG, Cytiva (a Danaher subsidiary), and Catalent, all of which offer similar scalable solutions.
Thermo Fisher’s Q1 2026 results showed a 6 % revenue increase to $11.01 billion and an adjusted EPS of $5.44, beating analyst expectations. The company raised its full‑year 2026 guidance following the strong quarter, reflecting confidence in continued demand for its cell‑therapy platform. The DynaXS launch is positioned to contribute to these growth trends by expanding the company’s product mix in a high‑growth segment.
Sara Henneman, vice president and general manager of Thermo Fisher’s cell culture and cell therapy business, said the DynaXS bioreactor “reflects our commitment to help deliver end‑to‑end, integrated solutions that enable customers to simplify scale‑up, strengthen process control, and support the development of therapies intended for patient use.” Senior director of research and development Andy Campbell added that the platform’s broad operating range and flexible design “enables customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types.”
By offering a single‑use, scalable system, the DynaXS platform addresses the industry’s shift from static culture systems to flexible, regulatory‑ready solutions. The product is expected to generate new revenue streams for Thermo Fisher and strengthen its competitive position in the rapidly expanding cell‑therapy manufacturing space, reinforcing the company’s one‑stop‑shop model for life‑sciences customers.
The launch signals Thermo Fisher’s continued investment in the cell‑therapy market and its strategy to provide end‑to‑end solutions that accelerate the development and commercialization of cell‑based therapies. As the market grows, the DynaXS bioreactor is poised to play a key role in enabling manufacturers to meet increasing demand while maintaining process control and regulatory compliance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.